Literature DB >> 2511290

Dosage of intravenously administered immune globulin and dosing interval required to maintain target levels of immunoglobulin G in low birth weight infants.

K S Kyllonen1, D W Clapp, R M Kliegman, J E Baley, N Shenker, A A Fanaroff, M Berger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2511290     DOI： 10.1016/s0022-3476(89)80761-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  7 in total

1.  Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis.

Authors:  K N Haque; C Remo; H Bahakim
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 2.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

Review 3.  Immunology of diseases associated with Malassezia species.

Authors:  H Ruth Ashbee; E Glyn V Evans
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Janet B Lacy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-29

5.  Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.

Authors:  J R Groothuis; M J Levin; W Rodriguez; C B Hall; C E Long; H W Kim; B A Lauer; V G Hemming
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

6.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

7.  Immunoglobulin serum levels in very low birth weight infants treated with different intravenous preparations.

Authors:  M Amato; D Markus; P Hüppi; P Imbach
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.